Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Waldenstrom Macroglobulinemia × Rituximab × Clear all

Phase

Phase 2 51 Phase 1/2 14 Phase 1 14 Phase 3 3 Phase NA 2 Phase EARLY_PHASE1 1 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Lymphoma, Non-Hodgkin 5 Leukemia, Lymphocytic, Chronic, B-Cell 4 Lymphoma, B-Cell, Marginal Zone 2 Waldenstrom Macroglobulinemia 1 Sjogren's Syndrome 1 Neoplasms 1 Neoplasm, Residual 1 Lymphoma, B-Cell 1 Lymphohistiocytosis, Hemophagocytic 1 Lymphatic Diseases 1 Leukemia, B-Cell 1 Leukemia 1 Heart Failure 1 Arthritis, Rheumatoid 1

Interventions

zanubrutinib 2 talquetamab 1 ibrutinib 1 Thiotepa 1 Thalidomide 1 Sirolimus 1 Rituximab 1 Radiotherapy 1 Prednisone 1 Filgrastim 1 Everolimus 1 Cyclophosphamide 1 Bortezomib 1 Antilymphocyte Serum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02844322 2026-02-11

BDH-WM01

Institute of Hematology & Blood Diseases Hospital, China

Phase 4 Completed

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡